C4 Therapeutics Inc (NAS:CCCC)
$ 4.31 0.12 (2.86%) Market Cap: 295.77 Mil Enterprise Value: 123.46 Mil PE Ratio: 0 PB Ratio: 1.26 GF Score: 60/100

C4 Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 06:30PM GMT
Release Date Price: $7.15 (+6.40%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Okay. We'll get started. I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. Our next presenting company is C4 Therapeutics and presenting on behalf of the company CEO, Andrew Hirsch. We'll be doing Q&A after the presentation in the room and for those viewing on the digital conference book, feel free to submit questions via the portal. So with that, Andrew.

Andrew J. Hirsch
C4 Therapeutics, Inc. - CEO, President & Director

Great. Thanks, Eric, and thanks for JPMorgan for having us here today. It's very exciting to actually be here in person and not presenting from my living room, which we did last year. I'm really excited to provide an update on the progress we've made at C4 Therapeutics over the past year, and we have upcoming in store for 2023.

But before I begin, I'll be making forward-looking statements, and this is our disclaimer on that matter, subject to risks and uncertainties that are outlined in the risk factors in our SEC statement. So C4

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot